Introduction
Cancer arises from the cellular accumulation of genetic alterations, leading to uncontrolled clonal proliferation (Hanahan and Weinberg, 2000) . These mutations can be broadly classifi ed into two categories. First, activation of a single allele of a gene which promotes cellular proliferation or survival (oncogene) can occur by point mutation, deletion, chromosomal fusion, gene amplifi cation or dysregulated expression. Secondly, homozygous inactivation of genes which inhibit tumourigenesis (tumour suppressor genes) can occur through any of the above mechanisms excluding gene amplifi cation. Furthermore, inactivation of a tumour suppressor gene may occur by a mutation in one allele that generates a dominant negative protein, causing functional inactivation of the other, wild-type, allele (Kern et al., 1992; Shounan et al., 1996; Shounan et al., 1997) . It has been demonstrated in a variety of systems that suppression of expression of one oncogene, or reinstatement of the function of one tumour suppressor gene (which, in some instances can be achieved by inhibiting expression of a dominant negative allele) can revert the transformed phenotype to normal and/or cause the death of the malignant cell (Brummelkamp et al., 2002b; Dolnikov et al., 2000; Kashani-Sabat et al., 1992; Martinez et al., 2002; Nielsen and Maneval, 1998; Scherr et al., 1998) . Consequently, there has been a substantial amount of research aimed at developing gene therapies or small molecule drugs which inhibit the expression of oncogenes or the activity of oncoproteins.
However, nearly three decades have elapsed since the discovery of the fi rst human oncogenes and, despite the concerted efforts of many researchers, effective therapies specifi cally targeting oncogenes or their protein products have proven to be frustratingly elusive. Whilst there has been some recent success with the small molecule tyrosine kinase inhibitor Imatinib in the treatment of chronic myeloid leukaemia (CML), the relatively rapid resistance to this drug which occurs in vivo limits its effi cacy (Druker et al., 2001b; Druker et al., 2001c; Gorre et al., 2001) . Furthermore, the frequency of Imatinib resistance is markedly increased in patients with more advanced disease, which is arguably more analogous to other forms of malignancy than the earlier chronic phase which may persist for years without serious adverse effects (Druker et al., 2001a) . These results emphasize the need for combinations of cancer therapies acting through different mechanisms to prevent the evolution of resistant disease (analogous to the cocktails of anti-retroviral drugs used in the treatment of HIV, to prevent the emergence of resistant strains of the virus). In this regard, oncogene suppression gene therapies still offer promise, due to their high specifi city and the fact that it is possible to use them in combination with other therapies.
Gene Suppression Technologies

Antisense
The use of antisense (reviewed in Pirollo et al., 2003) was the fi rst gene suppression strategy to be tested, and antisense approaches comprise the majority of gene therapy clinical trials to date for the treatment of cancer. Antisense therapeutics are generally small oligonucleotides composed of RNA, DNA or other nucleic acid analogues. They are complementary to a specifi c sequence in the target mRNA, and bind by standard Watson-Crick base pairing. This inhibits expression of the target gene by decreasing the stability of the target mRNA and/or inhibiting translation. Destabilisation of the mRNA can occur through a variety of mechanisms including induction of RNase H activity and inhibition of 5'-capping and 3'-polyadenylation (Crooke, 1999) . Inhibition of translation may occur through direct blocking of the ribosome, inhibition of splicing and interference with required RNA secondary structures (Crooke, 1999) . The most important characteristics of antisense oligonucleotides are those relating to in vivo stability, cellular uptake, specifi city/affi nity for the target mRNA and ability to suppress gene expression. Accordingly, a number of chemical modifi cations (primarily alterations in sugar and backbone structure) to antisense oligonucleotides have been devised, which optimize these parameters and thereby increase the effi cacy and decrease the toxicity of the therapeutic construct (Agrawal and Kandimalla, 2001) . In addition to the delivery of synthetic antisense molecules, antisense effects may also be produced through gene expression to produce antisense RNA intracellularly (Medina and Joshi, 1999) .
Antisense oligonucleotides can be used to target a wide range of oncogenic targets including over-expressed, point mutated and truncated oncogenes (Chang et al., 1991; Marcucci et al., 2003 , Rait et al., 1999 . Additionally, antisense approaches may be used to target fusion transcripts in which two cellular genes have become fused leading to the generation of an oncogenic fusion protein (Rapozzi et al., 2002) . The archetypal example of this is fusion of the Bcr and abl genes during formation of the Philadelphia Chromosome [t(9;22)], characteristic of CML, and which is the molecular target of Imatinib (Druker et al., 2001a) .
There are in excess of forty clinical trials of antisense therapeutics and more than half of these are for the treatment of cancer (these are discussed in greater detail below). However, more recently developed gene suppression technologies (RNAi and catalytic nucleic acids, see below) generally exhibit greater effi cacy than antisense both in vitro and in animal models. It seems likely, assuming that safety issues do not compromise the development of these other technologies, that they will eventually supplant antisense.
Catalytic Nucleic Acids: Ribozymes and Deoxyribozymes.
Ribozymes are small single stranded RNA molecules which have the ability to catalyze the site-specifi c cleavage of RNA phosphodiester bonds. The fi rst known ribozymes were found in the group I intervening sequence of the pre-RNA of Tetrahymena thermophilia (Cech et al., 1981; Kruger et al. 1982) . This sequence catalyses its own excision and, because it cleaves within itself, is termed cis acting. Since that discovery, a number of ribozymes with distinctive structural motifs (hammerhead, hairpin, axehead, etc) have been discovered in a number of organisms (Branch and Robertson, 1991; Buzyan et al., 1986; Forster and Symons, 1987; Guerrier-Takada et al., 1983; Hutchins et al., 1986) and, several of these structural motifs (most notably the hammerhead and hairpin) have been shown able to cleave target sequences in trans (Haseloff and Gerlach, 1988; Uhlenbeck, 1987) . The signifi cance of ribozymes which can act in trans is that it is possible to design and construct ribozymes which suppress gene expression through the targeting of specifi c mRNA transcripts.
The most widely used and studied of the ribozyme structural motifs is the hammerhead ribozyme. The trans acting hammerhead ribozyme (Figure 1 ) developed by Haseloff and Gerlach in 1988 has minimal substrate requirements and has become the standard model for hammerhead ribozyme design. The only sequence requirement in the substrate is the presence of an NUX sequence where N is any base and X is any base other than G, although, with some variation in effi cacy (Zoumadakis and Tabler, 1995) . Substrate specifi city is determined by standard Watson-Crick base pairing between the two fl anking arms of the ribozyme and the RNA substrate. Once the ribozyme has bound the substrate, the phosphodiester bond immediately 3' of the NUX sequence is cleaved in a reaction involving activation of the 2'-hydroxyl as a nucleophile (Kumar and Ellington, 1995) . Breaking of the hydrogen bonds then results in dissociation of the two RNA strands and the ribozyme is free to catalyze another substrate.
The high sequence specificity of ribozymes has sparked a great deal of interest in their use to target mRNA molecules in trans. Through this strategy, specifi c inhibition of the expression of genes or even mutated versions of genes has been shown to be possible (reviewed in Bramlage et al., 1998) . As a specifi c example, ribozymes have been designed that will not cleave normal ras transcripts but that will cleave mutated (oncogenic) ras transcripts, which differ from their cellular homologues by a single point mutation (Scherr et al., 1997) . Delivery of such an anti-ras ribozyme has been shown to reverse mutant ras associated transformation of both fi broblast (KashaniSabet et al., 1992) and haematopoietic cells (Scherr et al., 1998 , Dolnikov et al., 2003 .
Ribozymes targeting Bcr-abl have been shown to decrease expression of the fusion gene and inhibit cell proliferation in vitro (Snyder et al., 1993; Warashina et al., 1999) . Furthermore, anti-Bcr-abl ribozymes have been demonstrated to prevent tissue invasion by leukemic cells and to prolong survival in a murine model of CML (Tanabe et al., 2000) . Ribozymes targeting the PML/RARα fusion [t(15;17) ] characteristic of acute promyelocytic leukemia (Nason-Burchenal et al., 1998) and the AML1/MTG8 fusion [t(8;21) ] associated with acute myeloid leukemia (Matsushita et al., 1995) have also been demonstrated to be effective in tissue culture systems.
As for antisense, ribozymes may be delivered into a target cell in two ways. First, a synthetic RNA oligonucleotide of the ribozyme may be transfected into a cell directly using a standard transfection technique (commonly lipofection, although for clinical trials delivery of naked RNA is more common). Secondly, a "gene" coding for the ribozyme may be delivered into the cell, transcription of which then generates the active ribozyme . With respect to oncogene suppression therapies, the former of these delivery techniques is complicated by the short half-life of these molecules in vivo caused by the inherent instability of single-stranded RNA molecules in biological systems; indeed, the instability of RNA and the cost of generating RNA in vitro are both signifi cant disadvantages of the use of exogenously delivered RNA molecules. The latter delivery method may be complicated by the problems associated with viral gene delivery, which are discussed in detail below.
One solution to the problem of synthetic ribozyme instability is the use of DNA enzymes (deoxyribozymes, DNazymes, Reviewed in Cairns et al., 2002 and Kachigian, 2000) , which take advantage of the signifi cantly increased stability of single-stranded DNA compared with singlestranded RNA in biological systems . The most effi cient RNA cleavage by a DNA enzyme is thought to be that of the so-called 10-23 DNazyme, which was identifi ed by an in vitro selection process (Santoro and Joyce, 1997) , and which has been used to target the expression of several genes associated with human malignancy including myc, PKC and Bcr-abl (Sioud and Leirdal, 2000; Sun et al., 1999; Warashina et al., 1999) .
RNA Interference
In the last two years, the phenomenon of RNA interference (RNAi) has emerged as an effi cient and selective technique for gene suppression. RNAi is mediated by small (19-23 nucleotides) double stranded RNA molecules (siRNAs or shRNAs, see below), which silence gene expression in a sequence specifi c manner (Caplen et al., 2001; Elbashir et al., 2001 ). An attractive feature of RNAi, both as a research tool and as a potential therapeutic, is the extremely high level of gene suppression that is achievable. In many cases, the expression of the target gene is suppressed to levels that are undetectable by Western blotting (Brummelkamp et al., 2002a; Brummelkamp et al., 2002b) .
In mammalian cells, RNAi can be triggered by two distinct forms of dsRNA, short interfering RNAs (siRNAs) (Elbashir et al., 2002) and short hairpin RNAs (shRNAs) (Brummelkamp et al., 2002a; . Current models suggest that shRNAs are processed into siRNAs by the enzyme dicer in an ATP dependent process. siRNAs are then incorporated into the multi-protein RNA Induced Silencing Complex (RISC) in a second ATP dependent step, and mediate the targeting of specifi c single stranded RNA sequences for cleavage and subsequent degradation ( Figure 2 ). As with antisense and ribozymes, siRNAs can be delivered directly into a cell or a gene expression construct can be introduced. In general, siRNAs are delivered directly and shRNAs are generated intracellularly by transcription, however, strategies have been devised for the intracellular generation of siRNAs by transcription of a short sequence in both directions . Delivery of RNAi triggers using retroviral and adenoviral vectors has been demonstrated (Brummelkamp et al., 2002b . Several groups have demonstrated that systemic delivery of naked siRNAs in mice can have a signifi cant impact upon the expression of either a co-transfused transgene McCaffrey et al., 2002) or an endogenous gene (Song et al., 2003) . The latter has, thus far, only been demonstrated in the liver, which is a highly accessible target tissue.
In contrast to antisense and (in general) ribozymes and DNazymes, even a single base discrepancy between the siRNA and target mRNA transcript is suffi cient to signifi cantly abrogate the suppressive effect (Semizarov et al., 2003) . This extreme specificity has significant implications for the potential use of RNAi as a therapeutic modality for cancer. First, there is the potential (as detailed for ribozymes above) to use RNAi to selectively inhibit expression of oncogenes containing a single point mutation without affecting expression of the wild-type transcript, which may have an essential cellular function. For example, Brummelkamp and coworkers (Brummelkamp et al., 2002b) recently utilized a retrovirally delivered shRNA specifi c for a mutant K-ras allele to inhibit the tumourigenicity of cells which expressed this oncogene, and they demonstrated that this did not affect expression of the wild-type allele.
As with antisense and ribozymes, RNAi based therapies are potentially amenable to the targeting of oncogenic transcripts in which two cellular genes have become fused leading to the generation of an oncogenic fusion protein.
Several groups have shown that siRNAs targeted to the fusion point of the Bcr-abl transcript decrease expression of the oncogene and induce apoptosis in Bcr-abl positive cells (Scherr et al, 2002; Wilda et al., 2002; Wohlbold et al., 2003) . Furthermore, there is evidence that anti-Bcr-abl siRNAs synergise with Imatinib treatment, even in cells which express Imatinib-resistant Bcr-abl (Wohlbold et al., 2003) suggesting that this may be a useful agent for combination therapy with Imatinib.
Targets and Resistance.
It can be seen that the use of gene suppression technologies is potentially applicable for the targeting of all oncogenic fusion transcripts (e.g. Bcr-abl, PMLRARα, AML1/MTG8) and that ribozymes, DNAzymes and RNAi (and, in rare cases, antisense) are applicable for the targeting of oncogenes containing a single, activating point mutation (e.g. ras). However, the targeting of oncogenes which are over expressed as a wild-type transcript (e.g. myc) or genes which are truncated (e.g. EGFR) by these techniques is not so obviously useful, since unselective suppression of such genes in non-tumour tissues may cause toxicity (see Table 1 ). In such cases, targets need to be assessed on an individual basis, where specifi city for the malignant tissue may be conferred not by tumour specifi c gene suppression but by an "enhanced" tumour specifi c requirement of the target gene. As an example, overexpressed bcl-2 is a valid target for gene suppression therapies because it is required for the survival of malignant tissue, but not required for the survival of most normal tissues Marcucci et al., 2003 , Waters et al., 2000 . An important lesson learned from the use of Imatinib is that therapies which combine high specifi city with high effi cacy exert a strong selective pressure for the emergence of mutations that confer resistance (Gorre et al., 2001; Shah et al., 2002) . In view of this, it may be that the extremely high specifi city of RNAi will be disadvantageous with respect to the potential use of this technology for the treatment of cancer, since, a single mutation in any of the 19 to 23 base pairs which constitute the siRNA target sequence in the transcript may lead to rapid resistance. Moreover, given the redundancy of the genetic code, virtually any target sequence will contain bases that may be substituted without a corresponding alteration in the cognate translated peptide (silent mutation, Figure 3 ). The implication of this is that resistance to RNAi mediated therapy could be generated with no diminution of function in the oncoprotein, and such therapies are likely to require a combination of RNAi triggers targeted to multiple sites in the target transcript and/or to multiple transcripts. The evolution of resistance to ribozyme based therapies is likely to cause similar problems, although resistance would be expected to occur with lower frequency because it is likely that only mutations in the NUX cleavage site would completely abolish ribozyme activity. Resistance to antisense therapies may be less common than resistance to RNAi, DNAzyme or ribozyme therapies, since several mutations in the target sequence would be required to diminish gene suppression.
Vectors and Delivery
For gene suppression therapies, as for all gene therapies, a major challenge to be overcome is the development of technologies capable of effi cient delivery of nucleic acids into target cells. Pfeiffer and Verma (Pfeiffer and Verma, 2001 ) have delineated six characteristics of an ideal gene therapy vector: 1) ease of production, 2) safety, 3) sustained and regulatable gene expression, 4) target cell specifi city, 5) ability to transduce both dividing and nondividing cells, and 6) site-specifi c integration. However, for cancer gene therapies, the ability to transduce nondividing cells is likely dispensable, since malignant cells are generally in cycle. Furthermore, if the objective of the Yes (Martinez, 2003) Truncated gene Yes † † (Rait, 1999) Yes † † (Juhl, 1997) Yes † † (Nagy, 2003) Over-expressed Oncogene Yes † † (Marcucci, 2003) Yes † † (Luzi, 2003) Yes † † (Cioca, 2003 ) * Applicable in a very limited number of specifi c instances. † Antisense is not capable of absolute discrimination between the wild-type and mutant transcripts. † † Will also affect expression of the wild type gene; Only applicable in cases where suppression of the wild-type gene is non-toxic. therapy is to destroy the malignant tissue relatively rapidly and not to revert the phenotype to normal, both sustained and regulatable expression, and site-specifi c integration can also be dismissed. The issue of cell-specifi city tends to be dependent upon the "cargo" of the vector. In some gene therapy vectors target-cell specifi city is elicited intracellularly (e.g. cell type specifi c promoters/enhancers, ribozymes or siRNAs targeted to oncogenic alleles) whereas others are restricted through transduction of a specifi c target cell population. In general, cancer gene suppression strategies rely on the former. Thus, for cancer gene therapies, the single most important characteristic of a vector is the ability to safely transduce cells at high effi ciency.
Viral Vectors
To date, the majority of research on gene therapy vectors has concentrated on modifi ed viruses as a means of nucleic acid delivery. These viral vectors can be broadly classifi ed into two categories, those which integrate into the genome of the target cell (Retroviral including Lentiviral and Adeno-Associated Viral vectors) and those which do not (Adenoviral vectors). In general, viral vectors are internally deleted versions of the wild-type virus, in which only those elements required for infection and delivery of the gene of interest (transgene) into the target cell are retained. Commonly, viral proteins required for production of the viral particle but not for infection are supplied in trans from a packaging construct. Consequently, the viral particles generated are capable of infection of a target cell and delivery of the transgene but are not capable of replication and generally do not exhibit pathogenicity (Pfeiffer and Verma, 2001) .
Of the vectors which integrate stably into the genome of the target cell, simple retroviral vectors have received the most attention. Retroviruses are single-stranded RNA viruses (reviewed in Buchschacher, 2001) . Upon entry into the target cell, the RNA genome of the virus is reverse transcribed, generating double stranded DNA which integrates into the host genome. Most retroviral vectors are based on the Moloney Murine Leukemia Virus (MoMLV) and these were the fi rst vectors to be used in human gene therapy trials. As noted above, retroviral vectors are internally deleted versions of the wild-type virus, in which the viral replicative genes have been replaced with the gene of interest. (Brummelkamp et al., 2002b; Buchschacher, 2001; Dolnikov et al., 2003) More recently, vectors derived from more complex retroviruses (lentiviruses) have been developed (reviewed in Quinonez and Sutton, 2002) . The principle advantage of these vectors, when compared with earlier retroviral vectors, is that they are capable of infecting quiescent cells. However, because of their increased complexity and the fact that many of these vectors are based on viruses Figure 3 . Potential resistance to RNAi based therapies through silent mutation. Because even a single nucleotide discrepancy between the siRNA (top) and target mRNA abrogates gene suppression, there is broad scope for the emergence of point mutations which, due to the redundancy of the genetic code, do not alter the sequence of the translated peptide.
with greater pathogenicity (e.g. HIV) than the more simple retroviruses, these vectors are less facile to utilize and will require extensive safety testing before trials in humans.
The predominant non-integrating viral vector systems are those based on adenoviruses (reviewed in Bauerschmitz et al., 2002) . Wild-type adenoviruses have double stranded DNA genomes of approximately 36 kb in length. Adenoviral vectors can accommodate large inserts, and can be produced at high titres (up to 10 14 infectious particles/ml). However, signifi cant toxicities have been shown to be associated with the use of adenoviral vectors including both adaptive and innate immune responses (St George, 2003) . To the best of our knowledge, adenoviral vectors have not been used in clinical trials for cancer gene suppression therapies to date, although, they are currently in Phase III clinical trials for replacement of the p53 tumour suppressor gene in the treatment of squamous cell carcinoma (an updated list of ongoing clinical trials can be found at http://www.clinicaltrials.gov).
There are a variety of problems complicating the use of viral vectors in vivo. Overall for all viral vectors these include, but are not limited to: rapid in vivo destuction of virions, immunogenicity of the viral proteins, the potential for insertional mutagenesis with certain vectors and the potential for recombination of the viral vector during production. For these reasons, none of the cancer gene suppression therapies which have progressed to clinical trials so far have employed viral vectors. It should be noted, however, that viral vectors have been used clinically in other cancer gene therapy strategies including the adenoviral delivery of p53 mentioned above and the selectively replicating adenovirus ONYX-015 (Nemunaitis et al., 2003) .
Non-Viral Delivery
Because of the challenges associated with viral delivery of nucleic acids, many gene therapy strategies involve non-viral delivery protocols. These may involve delivery of naked nucleic acid, microencapsulation (Jackson et al., 2002) , or the use of a complexing agent. Complexing protocols generally involve the use of cationic polymers, such as positively charged peptides and chitosan (Brown et al., 2001; Guang Liu and De Yao, 2002) , or the use of lipoplexes (discussed below). In terms of clinical application, two of these non-viral delivery systems predominate: delivery of naked nucleic acids and delivery of cationic liposome/nucleic acid formulations.
Delivery of naked nucleic acid can be performed via a number of routes, the most used being intratumoural injection and intravenous infusion (Pirollo et al., 2003) . Nearly all of the cancer gene suppression clinical trials to date have employed intravenous infusion of a naked construct, with intratumoural injection being second most common. Dose limiting toxicities observed with intravenous infusion of naked nucleic acid tend to be similar regardless of the target and include fatigue, fever, hypotension and thrombocytopenia (Pirollo et al., 2003) . Whilst these toxicities are relatively mild, the major limitation of this delivery technique is that it is extremely ineffi cient, with little clinical evidence of gene suppression (Yuen et al., 2001) .
Attempts to increase the efficiency of in vivo transfection using chemical formulations have mainly focussed upon lipoplexes (reviewed in Audouy et al., 2002) . These are complexes of nucleic acids with cationic liposomes, which act to facilitate the entry of nucleic acids into cells via endocytosis. This approach has been demonstrated to improve in vivo transfection compared with delivery of naked nucleic acid, however, the liposomal reagents themselves can induce dose limiting toxicities (Dass, 2002) . In addition, some cationic liposomes are no less immunogenic than are some viral vectors, and further testing of these formulations is required.
Clinical Application
For cancer gene suppression therapies, the choice of target gene is crucial to the potential success of the therapeutic approach. This choice is complicated by the enormous range of potential targets. Even within a single malignant clone there will be several targetable genes, suppression of which may potentially inhibit neoplasia. The range of targets within a single clone is small, however, when compared to the variety of genes which are mutated in human malignancies. Only a small fraction of these will be present as the mutated gene in a given tumour. One approach to tackling this problem has been to target genes which occur at high frequency in human malignancies (e.g. ras, myc) since these are assumed to be of greater signifi cance to the neoplastic phenotype than those mutations which occur less frequently, and therapies aimed at such genes will be applicable to a greater number of cases. However, frequency is not necessarily a good indication of the suitability of an oncogene for targeting, since frequency is unrelated to the potential phenotypic effect of suppressing such a gene. One can argue that there is, in fact, only a single primary criterion for selection of a target gene -namely that suppression of the gene (either alone or in combination with another therapy) induces a permanent abrogation of the neoplastic phenotype. However, the inherent genomic instability of malignant cells (Hanahan and Weinberg, 2000) combined with the large number of mutations already present in such cells by the time of clinical presentation, implies that suppression of a single gene may not be capable of inducing a permanent reversal of phenotype. One can then argue that destruction of the malignant clone is the most practicable strategy. With this in mind, there are, hypothetically, six general classes of gene which may be targeted by gene suppression therapies for the treatment of cancer (Table 2) , corresponding to the six acquired phenotypic characteristics of malignant cells as defi ned by Hanahan and Weinberg (Hanahan and Weinberg, 2000) . These are: 1) genes which inhibit apoptosis, 2) stimulate proliferation, 3) induce angiogenesis, 4) confer metastatic potential, 5) impart immortality and 6) disrupt tumour suppressive function. The situation is complicated in practice, however, by the fact that many of the genetic mutations associated with malignancy contribute to more than one of these phenotypic characteristics.
Anti-Apoptosis.
There are two possible mechanisms by which a gene product may prevent apoptosis. Either, the protein may directly inhibit the apoptotic machinery or it may confer resistance to external apoptotic stimuli including chemotherapeutic compounds. Of the former, the bcl-2 gene (which prevents the release of Cytochrome C from the mitochondria, reviewed in Cory and Adams, 2002) has received the most attention as a potential molecular target (Waters et al., 2000) . Ribozymes, siRNAs and antisense molecules targeted to bcl-2 have all been shown to induce apoptosis and to increase chemosensitivity in malignant cells of several different origins in a variety of tissue culture systems (Campos et al., Blood 1994; Cioca et al., 2003; Luzi et al., 2003; van de Donk et al., 2003; Ziegler et al., 1997) . Furthermore, animal studies using the phosphorothioate modifi ed oligonucleotide Genasense (Oblimersen Sodium, G3139) have demonstrated the effi cacy of this bcl-2 antisense molecule both alone and in combination with chemotherapy (Jansen et al., 1998; Klasa et al., 2000; Konopleva et al., 2000; Schlagbauer-Wadl et al., 2000) . Phase I and II clinical trials have subsequently shown that this compound is relatively safe Marcucci et al., 2003 , Waters et al., 2000 , although the clinical impact appeared to be modest. Initial reports from a Phase III clinical trial of Genasense in combination with Dacarbazine for the treatment of advanced malignant Melanoma have been suffi ciently promising that a New Drug Application has been initiated with the Food and Drug Administration (Genta press release, September 10, 2003) . To date, however, the results from this trial have not been clear, and a longer follow-up is required to prove statistically signifi cant effi cacy on an intent-to-treat basis. Additional Phase III clinical trials for Chronic Lymphocytic Leukaemia, Multiple Myeloma and Lung Cancer are currently under way.
The other class of oncogenes that prevent apoptosis are those which confer resistance to external apoptotic stimuli. Amongst these, the MDR1 gene which encodes the drug effl ux pump P-glycoprotein has attracted the most attention as a target for clinical intervention. Antisense (Astriab-Fisher et al., 2000) , ribozymes (Scanlon et al., 1994) and siRNAs (Wu et al., 2003) have all been used to target MDR1, and all have demonstrated the ability to restore drug sensitivity in tissue culture systems. However, the only anti-MDR1 agents which have progressed to clinical trials are small molecule antagonists.
Proliferation.
A number of different gene suppression strategies have been devised targeting a range of genes which stimulate the proliferation of malignant cells. Prominent amongst these target genes are members of the erb gene family, including both the epidermal growth factor receptor (EGFR) and the Her2 oncogene (reviewed in Klapper et al., 2000) . Antisense (Rait et al., 1999) , ribozyme (Juhl et al., 1997) and RNAi (Nagy et al., 2003) strategies targeting erb family members have all been shown to inhibit the proliferation of malignant cells in vitro and an anti-Her2 ribozyme (Herzyme™) is in Phase I clinical trials. In addition, a range of signal transduction molecules including members of the ras, raf and protein kinase families have been targeted using antisense (Chang et al., 1991; Dean et al., 1996; Monia et al., 1996) , ribozyme (Sioud and Sorensen, 1998) and RNAi (Brummelkamp et al., 2002b; Leirdal and Sioud, 2002) based strategies. These agents have all shown effi cacy in vitro and in xenograft models, however, those antisense molecules which have progressed to clinical trials, whilst relatively well tolerated, have generally not demonstrated high effi cacy Coudert et al., 2001 , Dang et al., 2001 . The exception was ISIS 3521, an antisense oligonucleotide targeting the PKC-α gene. In a Phase II clinical trial for the treatment of non-small cell lung cancer (Yuen et al., 2001) this agent, appeared to synergise with chemotherapy (20 of 53 patients demonstrated an objective response), however, a Phase III clinical trial for the same disease showed no signifi cant difference between patients receiving ISIS 3521 and those receiving chemotherapy alone (Lynch et al., 2003) . Thus, oncogenes that stimulate proliferation (although, none of those listed above are solely linked to proliferation and play important roles in other aspects of malignancy) have not yet been shown to be effective as targets for gene therapies.
Angiogenesis.
Anti-angiogenic therapies have primarily focused upon the Vascular Endothelial Growth Factor (VEGF) gene, which is a critical mediator of angiogenic signaling (Carmeliet and Jain, 2000) . Various strategies have been employed to suppress the expression of VEGF or the VEGF receptor including siRNA, antisense, and ribozymes (Cheng et al., 1996; Zhang et al., 2003) . However, despite showing some effi cacy in tissue culture and/or animal models, few of these have progressed to clinical trials. The exception is the so-called Angiozyme™, a ribozyme targeted to the VEGF receptor . This molecule has demonstrated anti-tumour activity in animal models (Pavco et al., 2000 : Sandberg et al., 1999 , has been shown to be safe in humans (Sandberg et al., 2000) and a Phase II trial for the treatment of Colorectal Cancer is under way. However, competing technologies such as monoclonal antibodies and small molecule inhibitors may prove to be more effective modalities for blocking angiogenic signaling through this pathway.
Metastasis.
To the best of our knowledge, there is only a single instance of a gene suppression technology exclusively aimed at the prevention of metastasis. Namely, a ribozyme targeting expression of Matrix Metalloproteinase-9 (Hua and Muschel, 1996) . Suppression of this gene using antisense oligonucleotides (Spessotto et al., 2002) and RNAi has also been demonstrated (Sanceau et al., 2003) but assessment of metastatic potential was not the primary focus of these studies.
Immortalty.
Immortality (the abrogation of proliferative senescence) is a characteristic of all human malignancies. In the majority of tumours immortality is conferred by the telomerase enzyme, which maintains the tandem hexameric repeat caps (telomeres) at the ends of chromosomes and is not expressed in most somatic tissues, making it an ideal target for cancer therapies (reviewed in Shay and Wright, 2002) . Telomerase is ribonucleoprotein which has two major components: an integral RNA component (hTERC) and the reverse trascriptase subunit (hTERT), both of which are essential for telomerase function. hTERC has been effectively targeted by number of groups using antisense oligonucleotides (Corey, 2002) , ribozymes (Kanazawa et al., 1996; Yokoyama et al., 1998) and siRNA (Kosciolek et al., 2003) . However, further pre-clinical testing of these agents is required in order to ensure that toxicities to stem cells (which express telomerase) and lack of effi cacy (related to the time lag between inhibition of telomerase and cell death in consequence of erosion of the telomeres) do not present signifi cant clinical obstacles.
Tumour Suppressors.
The reinstatement of innate tumour suppressive pathways in malignant cells is an extremely attractive therapeutic strategy. Reinstatement of previously inactivated tumour suppressor pathways using gene suppression techniques can be achieved in two ways. First, inhibition of the expression of a dominant negative allele of a tumour suppressor gene can restore wild-type function, since only a single functional allele of a classical tumour suppressor gene is required for induction and maintenance of the wildtype phenotype. For example, to suppress expression of a mutant, dominant negative allele of the p53 tumoursuppressor gene, ribozymes have been designed which repair (Watanabe and Sullenger, 2000) or degrade (Cai et al., 1995) the mutant transcript. Similarly, Martinez and co-workers (Martinez et al., 2002) demonstrated that by targeting a dominant negative allele of this gene with RNAi, it is possible to restore wild-type p53 function in cultured cells. The second mechanism by which reinstatement of tumour suppressor gene function can be effected is based on the observation that in some malignant cells tumour suppressor function is abrogated by the over expression of certain oncogenes. One example of this is over expression of the mdm2 gene, which encodes a p53-binding protein that mediates p53 degradation (reviewed in Michael and Oren, 2002) . Several groups have shown that a 20-mer antisense oligonucleotide to mdm2 induces p53 expression and retards growth of cancer cells in vitro (Meye et al., 2000; Tortora et al., 2000) . Furthermore, xenograft models have demonstrated that mdm2 antisense therapy synergises with chemotherapeutic agents, and is effective independent of the p53 status (wild-type or mutant) of the target cell (Wang et al., 2001 ).
Summary
Although signifi cant advances have been made in the search for specifi c inhibitors of oncogene expression, signifi cant obstacles remain. The available technologies can be effi cacious with respect to down-regulation of the target oncoprotein and can be suffi ciently specifi c. However, delivery of the therapeutic construct to a majority of cancerous cells is still a major impediment to clinical implementation. Despite a large number of clinical pilot studies, we are yet to see a proof-of-principal oncogene suppression therapy, which will demonstrate beyond doubt that this therapeutic strategy has clinical relevence. In this respect, the large number of ongoing clinical trials (mostly antisense oligonucleotide studies) are encouraging, and results of the Phase III trials of the bcl-2 antisense molecule Genasense will be particularly interesting. Looking to the future, RNAi and catalytic nucleic acids appear to hold much promise, and the higher efficacy of these technologies when compared with antisense strategies may be suffi cient to compensate for the relatively poor delivery that has been achieved to date.
